Celebrity Inventors
Comic actor Danny Kaye received patent D166,807 for the co-design of "Blowout Toy or the Like". It's similar to one of those toys that unravels when you blow into at a birthday party except Kaye's has three blowouts going in different directions, not just one.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120014990 | VACCINATION METHODS In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity. In another aspect, a method of boosting immune respo... | 01/19/2012 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110256174 | RABIES VACCINE An attenuated rabies virus for use as a vaccine. The attenuated rabies virus expresses an immune factor that enhances immune response upon administration of the vaccine.... | 10/20/2011 |
| 20110243979 | Method of Transcutaneous Immunization Using Antigen Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response. Use of skin-active adjuvants is p... | 10/06/2011 |
| 20110236419 | RECOMBINANT CDV COMPOSITIONS AND USES THEREOF The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. T... | 09/29/2011 |
| 20110217244 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSE The use of oxidatively transformed carotenoid or a component thereof to enhance the immune response in a subject for the treatment of infection or to enhance the immune response to an antigen in a subject being immunized. Also disclosed are pharmaceutical compositions a... | 09/08/2011 |
| 20110212123 | Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least ... | 09/01/2011 |
| 20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxi... | 07/28/2011 |
| 20110182939 | Vaccine Adjuvants The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-recept... | 07/28/2011 |
| 20110142912 | NON-SPECIFIC IMMUNOSTIMULATING AGENTS The present invention relates to the use of a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.... | 06/16/2011 |
| 20110081378 | COMPOSITION COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organism... | 04/07/2011 |
| 20110081380 | Stabilizing Excipient for Inactivated Whole Virus Vaccine The invention relates to a vaccine composition comprising:
| |
| 20110070264 | RABIES VIRUS VECTOR SYSTEMS AND COMPOSITIONS AND METHODS THEREOF Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions ... | 03/24/2011 |
| 20110020279 | RABIES CURE This invention is for a method of treatment of rabies once the patient develops signs and symptoms of rabies with the intent to save the patients from death and disability using insulin combined with various anti rabies viral therapeutic, pharmaceutical, biochemical, an... | 01/27/2011 |
| 20100297176 | Polyinosinic Acid - Polycytidylic Acid - Based Adjuvant The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with an antigen (e.g., as ... | 11/25/2010 |
| 20100278864 | Rabies Vaccine An attenuated rabies virus for use as a live vaccine. The attenuated rabies virus expresses an immune factor that enhances immune response upon administration of the live vaccine.... | 11/04/2010 |
| 20100260798 | Method for purifying the rabies virus The subject of the invention is a method for purifying the rabies virus, comprising a single ion-exchange chromatography step, said step being cation exchange chromatography according to which:
| 10/14/2010 |
| 20100247537 | ADJUVANT COMBINATIONS OF NKT ACTIVATOR, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is als... | 09/30/2010 |
| 20100189746 | ADAPTATION OF PITMAN MOORE STRAIN OF RABIES VIRUS TO PRIMARY CHICK EMBRYO FIBROBLAST CELL CULTURES The present invention relates to a process of adaptation of Pitman Moore strain of rabies virus to Primary chick fibroblast cells for the production of rabies vaccine.... | 07/29/2010 |
| 20100047279 | IMMUNOLOGICAL COMPOSITION The present invention relates to immunological compositions comprising sulpholipo-cyclodextrin (SL-CD) and, saponin or Quil A, and optionally at least one antigen. The invention relates to methods and immunological compositions comprising at least one antigen, which may... | 02/25/2010 |
| 20100047277 | VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC COMPOSITIONS Briefly described, virosomes, methods of preparing virosomes, immunogenic compositions that include virosomes, and methods of eliciting an immune response using immunogenic compositions that include virosomes are described herein. A virosome can include at least one vir... | 02/25/2010 |
| 20100034830 | Rabies vaccine The invention provides for an immunogenic rabies vaccine comprising a reduced vaccine dose and methods of pre- and post-exposure immunization with a reduced dose. The concentration of rabies vaccine antigen per dose is preferably less than 2.5 IU/mL.... | 02/11/2010 |
| 20100028383 | Chemically defined stabiliser The present invention relates to a stabiliser composition comprising an amino acid, and a sugar wherein all compounds are chemically defined; to a vaccine composition comprising such a stabiliser composition and a biological molecule and/or a micro-organism; to a method... | 02/04/2010 |
| 20090263421 | CELLULAR VACCINE The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nuc... | 10/22/2009 |
| 20090155303 | CPG SINGLE STRAND DEOXYNUCLEOTIDES FOR USE AS ADJUVANT The present invention provides an adjuvant, which includes at least one single strand deoxynucleotide containing a CpG dinucleotide. The single strand deoxynucleotide comprises one or more CpG dinucleotides. When used in combination with rabies vaccine, HBV vaccine or o... | 06/18/2009 |
| 20090155330 | Vaccine Delivery via Microneedle Arrays A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another ... | 06/18/2009 |
| 20090060948 | CATIONIC LIPID-MEDIATED ENHANCEMENT OF NUCLEIC ACID IMMUNIZATION OF CATS The present invention relates to a method to introduce a nucleic acid molecule into a fetid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic... | 03/05/2009 |
| 20090041852 | DRY POWDER COMPOSITIONS AND SYSTEMS FOR POULTRY VACCINATION This invention provides a dry powder composition for poultry vaccination via inhalation comprising an effective amount of a poultry vaccine agent, and a supporting amount of carriers for said poultry vaccine agent, said carriers comprising a combination of a reducing or... | 02/12/2009 |
| 20090041777 | Human antibodies against rabies and uses thereof Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.... | 02/12/2009 |
| 20090010964 | Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered w... | 01/08/2009 |
| 20080286295 | USE OF RECOMBINANT ANTIGENS TO DETERMINE THE IMMUNE STATUS OF AN ANIMAL The present invention includes a method to determine the immune status of an animal that includes the steps of (a) contacting a biological specimen of the animal with a recombinant infectious agent antigen that is specific for detecting an antibody selective for that in... | 11/20/2008 |
| 20080279886 | Safer Attenuated Virus Vaccines With Missing Or Diminished Latency Of Infection Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for... | 11/13/2008 |
| 20080233142 | Use of penetration enhancers and barrier disruption methods to enhance the immune response of an antigen A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemi... | 09/25/2008 |
| 20080206282 | Chimeric lyssavirus nucleic acids and polypeptides The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicit... | 08/28/2008 |
| 20080187556 | Medicine for Treating Tumor and Use Therefor in Preparation of the Medicaments for Treating Tumor Disclosed herein is a medicine comprising an active component of Rabies Vaccine for Human Use and methods of using thereof to treat tumors and HPV infections. The compositions and methods did not result in any observable side-effects in the experiments disclosed herein ... | 08/07/2008 |
